Quotes 5-day view Delayed Euronext Growth Paris
11/23/2020
11/24/2020
11/25/2020
11/26/2020
11/27/2020
Date
8.7(c)
8.01(c)
8.42(c)
8.43(c)
8.86(c)
Last
1 358 967
3 795 550
4 308 262
1 011 351
1 338 316
Volume
-2.14% -7.93% +5.12% +0.12% +5.10% Change
Sales 2020
296 M 355 M 355 M
Net income 2020
180 M 216 M 216 M
Net cash position 2020
6,85 M 8,19 M 8,19 M
P/E ratio 2020
3,47x
Yield 2020
-
Sales 2021
338 M 405 M 405 M
Net income 2021
183 M 219 M 219 M
Net Debt 2021
1,20 M 1,44 M 1,44 M
P/E ratio 2021
3,42x
Yield 2021
-
Capitalization
626 M 748 M 748 M
EV / Sales 2020
2,09x
EV / Sales 2021
1,85x
Nbr of Employees
110
Free-Float
99,3%
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. Net sales (not including sold divisions) break down by activity as follows:
- development of solutions and diagnostic services (51.8%). The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular...
News in other languages on NOVACYT
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVACYT
Short Term Mid-Term Long Term Trends Bearish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
2
Average target price
14,14 €
Last Close Price
8,86 €
Spread / Highest target
65,1%
Spread / Average Target
59,6%
Spread / Lowest Target
54,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
NOVACYT 5,142.60% 748
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
